EXELIXIS INC (EXEL) Stock Fundamental Analysis
NASDAQ:EXEL • US30161Q1040
44.08 USD
+0.16 (+0.36%)
At close: Feb 17, 2026
44.08 USD
0 (0%)
After Hours: 2/17/2026, 8:12:20 PM
EXEL gets a fundamental rating of 8 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. EXEL scores excellent points on both the profitability and health parts. This is a solid base for a good stock. EXEL scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make EXEL a good candidate for value and quality investing.
1. Profitability
1.1 Basic Checks
- EXEL had positive earnings in the past year.
- EXEL had a positive operating cash flow in the past year.
- In the past 5 years EXEL has always been profitable.
- Each year in the past 5 years EXEL had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 27.51%, EXEL belongs to the top of the industry, outperforming 97.70% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 36.21%, EXEL belongs to the top of the industry, outperforming 97.89% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 29.21%, EXEL belongs to the top of the industry, outperforming 98.85% of the companies in the same industry.
- Measured over the past 3 years, the Average Return On Invested Capital for EXEL is in line with the industry average of 18.69%.
- The 3 year average ROIC (18.74%) for EXEL is below the current ROIC(29.21%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 27.51% | ||
| ROE | 36.21% | ||
| ROIC | 29.21% |
ROA(3y)17.42%
ROA(5y)13.41%
ROE(3y)22.87%
ROE(5y)17.28%
ROIC(3y)18.74%
ROIC(5y)14.42%
1.3 Margins
- EXEL has a better Profit Margin (33.73%) than 96.55% of its industry peers.
- EXEL's Profit Margin has improved in the last couple of years.
- EXEL has a better Operating Margin (38.48%) than 97.89% of its industry peers.
- EXEL's Operating Margin has improved in the last couple of years.
- With an excellent Gross Margin value of 96.39%, EXEL belongs to the best of the industry, outperforming 96.35% of the companies in the same industry.
- In the last couple of years the Gross Margin of EXEL has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 38.48% | ||
| PM (TTM) | 33.73% | ||
| GM | 96.39% |
OM growth 3Y45.44%
OM growth 5Y28.11%
PM growth 3Y43.92%
PM growth 5Y24.4%
GM growth 3Y0%
GM growth 5Y0.01%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), EXEL is creating value.
- EXEL has less shares outstanding than it did 1 year ago.
- Compared to 5 years ago, EXEL has less shares outstanding
- There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 12.63 indicates that EXEL is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 12.63, EXEL belongs to the top of the industry, outperforming 84.64% of the companies in the same industry.
- EXEL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 12.63 |
ROIC/WACC3.37
WACC8.68%
2.3 Liquidity
- EXEL has a Current Ratio of 3.56. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
- EXEL's Current ratio of 3.56 is in line compared to the rest of the industry. EXEL outperforms 42.61% of its industry peers.
- A Quick Ratio of 3.50 indicates that EXEL has no problem at all paying its short term obligations.
- EXEL has a Quick ratio (3.50) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.56 | ||
| Quick Ratio | 3.5 |
3. Growth
3.1 Past
- EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 49.73%, which is quite impressive.
- Measured over the past years, EXEL shows a very strong growth in Earnings Per Share. The EPS has been growing by 51.25% on average per year.
- Looking at the last year, EXEL shows a small growth in Revenue. The Revenue has grown by 6.98% in the last year.
- EXEL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 18.63% yearly.
EPS 1Y (TTM)49.73%
EPS 3Y69.38%
EPS 5Y51.25%
EPS Q2Q%83.33%
Revenue 1Y (TTM)6.98%
Revenue growth 3Y12.93%
Revenue growth 5Y18.63%
Sales Q2Q%5.63%
3.2 Future
- Based on estimates for the next years, EXEL will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.92% on average per year.
- Based on estimates for the next years, EXEL will show a small growth in Revenue. The Revenue will grow by 7.52% on average per year.
EPS Next Y17.33%
EPS Next 2Y21.2%
EPS Next 3Y19.22%
EPS Next 5Y15.92%
Revenue Next Year11.13%
Revenue Next 2Y12.7%
Revenue Next 3Y12.02%
Revenue Next 5Y7.52%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 15.91 indicates a correct valuation of EXEL.
- Based on the Price/Earnings ratio, EXEL is valued cheaper than 95.97% of the companies in the same industry.
- EXEL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.16.
- EXEL is valuated correctly with a Price/Forward Earnings ratio of 13.56.
- Based on the Price/Forward Earnings ratio, EXEL is valued cheaper than 96.74% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 28.10. EXEL is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.91 | ||
| Fwd PE | 13.56 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, EXEL is valued cheaply inside the industry as 96.55% of the companies are valued more expensively.
- EXEL's Price/Free Cash Flow ratio is rather cheap when compared to the industry. EXEL is cheaper than 97.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.49 | ||
| EV/EBITDA | 11.05 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of EXEL may justify a higher PE ratio.
- A more expensive valuation may be justified as EXEL's earnings are expected to grow with 19.22% in the coming years.
PEG (NY)0.92
PEG (5Y)0.31
EPS Next 2Y21.2%
EPS Next 3Y19.22%
5. Dividend
5.1 Amount
- No dividends for EXEL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
44.08
+0.16 (+0.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-10 2026-02-10/amc
Earnings (Next)05-11 2026-05-11/amc
Inst Owners97.46%
Inst Owner Change-0.9%
Ins Owners2.18%
Ins Owner Change4.47%
Market Cap11.82B
Revenue(TTM)2.32B
Net Income(TTM)782.57M
Analysts74.81
Price Target46.75 (6.06%)
Short Float %10.66%
Short Ratio10.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.16%
Min EPS beat(2)7.04%
Max EPS beat(2)9.27%
EPS beat(4)4
Avg EPS beat(4)19.83%
Min EPS beat(4)7.04%
Max EPS beat(4)49.01%
EPS beat(8)7
Avg EPS beat(8)29.32%
EPS beat(12)9
Avg EPS beat(12)15.98%
EPS beat(16)13
Avg EPS beat(16)18.75%
Revenue beat(2)0
Avg Revenue beat(2)-1.79%
Min Revenue beat(2)-2.85%
Max Revenue beat(2)-0.72%
Revenue beat(4)1
Avg Revenue beat(4)0.68%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.27%
Revenue beat(12)4
Avg Revenue beat(12)2.32%
Revenue beat(16)6
Avg Revenue beat(16)1.65%
PT rev (1m)1.23%
PT rev (3m)4.42%
EPS NQ rev (1m)11.57%
EPS NQ rev (3m)28.55%
EPS NY rev (1m)1.7%
EPS NY rev (3m)13.74%
Revenue NQ rev (1m)-0.74%
Revenue NQ rev (3m)-0.96%
Revenue NY rev (1m)-0.25%
Revenue NY rev (3m)0.3%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.91 | ||
| Fwd PE | 13.56 | ||
| P/S | 5.09 | ||
| P/FCF | 13.49 | ||
| P/OCF | 13.37 | ||
| P/B | 5.47 | ||
| P/tB | 5.63 | ||
| EV/EBITDA | 11.05 |
EPS(TTM)2.77
EY6.28%
EPS(NY)3.25
Fwd EY7.37%
FCF(TTM)3.27
FCFY7.41%
OCF(TTM)3.3
OCFY7.48%
SpS8.65
BVpS8.06
TBVpS7.82
PEG (NY)0.92
PEG (5Y)0.31
Graham Number22.41
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 27.51% | ||
| ROE | 36.21% | ||
| ROCE | 36.6% | ||
| ROIC | 29.21% | ||
| ROICexc | 51.64% | ||
| ROICexgc | 54.14% | ||
| OM | 38.48% | ||
| PM (TTM) | 33.73% | ||
| GM | 96.39% | ||
| FCFM | 37.75% |
ROA(3y)17.42%
ROA(5y)13.41%
ROE(3y)22.87%
ROE(5y)17.28%
ROIC(3y)18.74%
ROIC(5y)14.42%
ROICexc(3y)32.95%
ROICexc(5y)27.65%
ROICexgc(3y)34.51%
ROICexgc(5y)29.16%
ROCE(3y)23.48%
ROCE(5y)18.07%
ROICexgc growth 3Y66.65%
ROICexgc growth 5Y32.48%
ROICexc growth 3Y66.54%
ROICexc growth 5Y33.67%
OM growth 3Y45.44%
OM growth 5Y28.11%
PM growth 3Y43.92%
PM growth 5Y24.4%
GM growth 3Y0%
GM growth 5Y0.01%
F-Score7
Asset Turnover0.82
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 29.01% | ||
| Cap/Sales | 0.36% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 95.93% | ||
| Profit Quality | 111.92% | ||
| Current Ratio | 3.56 | ||
| Quick Ratio | 3.5 | ||
| Altman-Z | 12.63 |
F-Score7
WACC8.68%
ROIC/WACC3.37
Cap/Depr(3y)95.03%
Cap/Depr(5y)177.94%
Cap/Sales(3y)1.3%
Cap/Sales(5y)2.02%
Profit Quality(3y)127.23%
Profit Quality(5y)142.21%
High Growth Momentum
Growth
EPS 1Y (TTM)49.73%
EPS 3Y69.38%
EPS 5Y51.25%
EPS Q2Q%83.33%
EPS Next Y17.33%
EPS Next 2Y21.2%
EPS Next 3Y19.22%
EPS Next 5Y15.92%
Revenue 1Y (TTM)6.98%
Revenue growth 3Y12.93%
Revenue growth 5Y18.63%
Sales Q2Q%5.63%
Revenue Next Year11.13%
Revenue Next 2Y12.7%
Revenue Next 3Y12.02%
Revenue Next 5Y7.52%
EBIT growth 1Y29.39%
EBIT growth 3Y64.24%
EBIT growth 5Y51.98%
EBIT Next Year12.21%
EBIT Next 3Y-11.05%
EBIT Next 5Y-5.67%
FCF growth 1Y30.42%
FCF growth 3Y37.77%
FCF growth 5Y37.42%
OCF growth 1Y26.33%
OCF growth 3Y34.6%
OCF growth 5Y33.44%
EXELIXIS INC / EXEL FAQ
What is the fundamental rating for EXEL stock?
ChartMill assigns a fundamental rating of 8 / 10 to EXEL.
Can you provide the valuation status for EXELIXIS INC?
ChartMill assigns a valuation rating of 8 / 10 to EXELIXIS INC (EXEL). This can be considered as Undervalued.
Can you provide the profitability details for EXELIXIS INC?
EXELIXIS INC (EXEL) has a profitability rating of 9 / 10.
Can you provide the financial health for EXEL stock?
The financial health rating of EXELIXIS INC (EXEL) is 9 / 10.
What is the expected EPS growth for EXELIXIS INC (EXEL) stock?
The Earnings per Share (EPS) of EXELIXIS INC (EXEL) is expected to grow by 17.33% in the next year.